Related references
Note: Only part of the references are listed.Next generation of immune checkpoint therapy in cancer: new developments and challenges
Julian A. Marin-Acevedo et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Dual Roles for Regulatory T-cell Depletion and Costimulatory Signaling in Agonistic GITR Targeting for Tumor Immunotherapy
Ashley E. Mahne et al.
CANCER RESEARCH (2017)
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
Paolo A. Ascierto et al.
LANCET ONCOLOGY (2017)
Characterization of MK-4166, a Clinical Agonistic Antibody That Targets Human GITR and Inhibits the Generation and Suppressive Effects of T Regulatory Cells
Selvakumar Sukumar et al.
CANCER RESEARCH (2017)
Intratumor and peripheral Treg modulation as a pharmacodynamic biomarker of the GITR agonist antibody TRX-518 in the first in-human trial
Roberta Zappasodi et al.
CANCER RESEARCH (2017)
Rationale for anti-GITR cancer immunotherapy
Deborah A. Knee et al.
EUROPEAN JOURNAL OF CANCER (2016)
First-in-human phase 1 single-dose study of TRX-518, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody in adults with advanced solid tumors
Henry B. Koon et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients
Emanuela Romano et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients
Brendan D. Curti et al.
CANCER RESEARCH (2013)
Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies
Yannick Bulliard et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy
David Coe et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok et al.
CLINICAL CANCER RESEARCH (2009)
Shortening the timeline of pediatric phase I trials: The rolling six design
Jeffrey M. Skolnik et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Critical aspects of the Bayesian approach to phase I cancer trials
Beat Neuenschwander et al.
STATISTICS IN MEDICINE (2008)
Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells
K Ko et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Glucocorticoid-induced TNF receptor functions as a costimulatory receptor that promotes survival in early phases of T cell activation
EM Esparza et al.
JOURNAL OF IMMUNOLOGY (2005)
Engagement of glucocorticoid-induced TNFR family-related receptor on effector T cells by its ligand mediates resistance to suppression by CD4+ CD25+ T cells
GL Stephens et al.
JOURNAL OF IMMUNOLOGY (2004)
Mouse glucocorticoid-induced tumor necrosis factor receptor ligand is costimulatory for T cells
M Tone et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Share Paper
